Article
Letairis Shows Efficacy and Safety in Children With PAH in Phase...
Rating:
0.0
Views:
60
Likes:
1
Library:
1
Letairis (ambrisentan), an approved therapy for pulmonary arterial hypertension (PAH) in adults, appears to also be effective and safe in children ages 8 and older, a study based on clinical trial data reports. All doses tested were well tolerated by children with PAH, and Letairis' benefit-risk...
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value